These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 22405252

  • 1. Management of Kawasaki disease: corticosteroids revisited.
    Son MB, Newburger JW.
    Lancet; 2012 Apr 28; 379(9826):1571-2. PubMed ID: 22405252
    [No Abstract] [Full Text] [Related]

  • 2. Critical review of: Efficacy of immunoglobulin plus prednisone for prevention of coronary artery prednisolone for prevention of coronary abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial.
    Etoom Y, Banihani R, Finkelstein Y.
    J Popul Ther Clin Pharmacol; 2013 Apr 28; 20(2):e91-4. PubMed ID: 23648367
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
    Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
    Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
    [Abstract] [Full Text] [Related]

  • 4. [Prednisolone therapy for Kawasaki disease].
    Kobayashi T, Kobayashi T, Arakawa H.
    Nihon Rinsho; 2014 Sep 28; 72(9):1623-8. PubMed ID: 25518413
    [Abstract] [Full Text] [Related]

  • 5. Kawasaki disease: an essential comparison of coronary artery aneurysm criteria.
    Burns JC, Hoshino S, Kobayashi T.
    Lancet Child Adolesc Health; 2018 Dec 28; 2(12):840-841. PubMed ID: 30337184
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin.
    Dale RC, Saleem MA, Daw S, Dillon MJ.
    J Pediatr; 2000 Nov 28; 137(5):723-6. PubMed ID: 11060542
    [Abstract] [Full Text] [Related]

  • 7. Treatment of Kawasaki disease: corticosteroids revisited.
    Newburger JW.
    J Pediatr; 1999 Oct 28; 135(4):411-3. PubMed ID: 10518072
    [No Abstract] [Full Text] [Related]

  • 8. Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease.
    Brogan P, Levin M.
    Evid Based Med; 2013 Dec 28; 18(6):217-8. PubMed ID: 23564929
    [No Abstract] [Full Text] [Related]

  • 9. Primary cytomegalovirus infection, atypical Kawasaki disease, and coronary aneurysms in 2 infants.
    Catalano-Pons C, Quartier P, Leruez-Ville M, Kaguelidou F, Gendrel D, Lenoir G, Casanova JL, Bonnet D.
    Clin Infect Dis; 2005 Sep 01; 41(5):e53-6. PubMed ID: 16080076
    [Abstract] [Full Text] [Related]

  • 10. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
    Kimura M, Harazaki M, Fukuoka T, Asakura I, Sakai H, Kamimaki T, Ohkawara I, Akiyama N, Tsurui S, Iwashima S, Shimomura M, Morishita H, Meguro T, Seto S.
    Pediatr Int; 2017 Apr 01; 59(4):397-403. PubMed ID: 27743415
    [Abstract] [Full Text] [Related]

  • 11. Recent developments and controversies in Kawasaki disease.
    Guzman-Cottrill JA, Shulman ST.
    Minerva Pediatr; 2004 Feb 01; 56(1):51-61. PubMed ID: 15249914
    [Abstract] [Full Text] [Related]

  • 12. Treatment of Kawasaki disease with corticosteroid.
    Shinohara M, Sone K, Kobayashi T, Kobayashi T, Kosuda T, Okada Y.
    J Pediatr; 1996 Sep 01; 129(3):483-4; author reply 484-5. PubMed ID: 8804350
    [No Abstract] [Full Text] [Related]

  • 13. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.
    Goto M, Miyagawa N, Kikunaga K, Miura M, Hasegawa Y.
    Endocr J; 2015 Sep 01; 62(2):145-51. PubMed ID: 25342092
    [Abstract] [Full Text] [Related]

  • 14. What dose of aspirin should be used in the initial treatment of Kawasaki disease?
    Ho LGY, Curtis N.
    Arch Dis Child; 2017 Dec 01; 102(12):1180-1182. PubMed ID: 29066520
    [No Abstract] [Full Text] [Related]

  • 15. Mucocutaneous lymph node syndrome in Calabar--a case report.
    Ikpatt NW, Ibia EO.
    East Afr Med J; 1989 Nov 01; 66(11):776-81. PubMed ID: 2606022
    [Abstract] [Full Text] [Related]

  • 16. [Kawasaki disease: what you need to know].
    Bajolle F, Laux D.
    Arch Pediatr; 2012 Nov 01; 19(11):1264-8. PubMed ID: 22921712
    [Abstract] [Full Text] [Related]

  • 17. Kawasaki disease. Involution of giant coronary aneurysms after prolonged anti-inflammatory treatment.
    Atik E, Foronda A, Bustamante LN.
    Arq Bras Cardiol; 2003 Sep 01; 81(3):265-72. PubMed ID: 14649251
    [No Abstract] [Full Text] [Related]

  • 18. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab].
    Salguero JS, Durán DG, Peracaula CS, Iznardi CR, Tardío JO.
    An Pediatr (Barc); 2010 Nov 01; 73(5):268-71. PubMed ID: 20678974
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW.
    J Pediatr; 2011 Apr 01; 158(4):644-649.e1. PubMed ID: 21129756
    [Abstract] [Full Text] [Related]

  • 20. Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome.
    Rigante D, Andreozzi L, Fastiggi M, Bracci B, Natale MF, Esposito S.
    Int J Mol Sci; 2016 Feb 24; 17(3):278. PubMed ID: 26927060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.